All In Biotech

Drug Trial Radar · NCT04683003

A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

A Phase 3b, Prospective, Open-label, Multicenter, Single Treatment Arm, Continuation Study of the Safety and Efficacy of TAK-755 (rADAMTS13, Also Known as BAX 930/SHP655) in the Prophylactic and On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP; Upshaw-Schulman Syndrome, or Hereditary Thrombotic Thrombocytopenic Purpura)

Last checked: Nov 19, 2026Latest source record: Apr 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

77

Planned (sponsor's estimate)

Start

Apr 14, 2021

Primary completion

Mar 16, 2027

Study completion Mar 16, 2027

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
Collaborators
Takeda Development Center Americas, Inc.; Shire
First posted
Dec 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 0 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Thrombotic thrombocytopenic purpura (or TTP for short) is a condition where blood clots form in small blood vessels throughout the body. The clots can limit or block the flow of oxygen-rich blood to the body's organs, such as the brain, kidneys, and heart. As a result, serious health problems can develop. The increased clotting that occurs in TTP uses up the cells that help the blood to clot, called platelets. With fewer platelets available in the blood, bleeding problems can also occur. People who have TTP may bleed underneath the skin forming purple bruises, or purpura. TTP also can cause anemia, a condition in which red blood cells break apart faster than the body can replace them, leading to fewer red blood cells than in normal. TTP is caused by a lack of activity in the ADAMTS13 enzyme, a protein in the blood involved in controlling clotting of the blood. The ADAMTS13 enzyme breaks up another blood protein called von Willebrand factor that forms blood clots by clumping together with platelets. Some people are born with this condition, while others develop the condition during their life. Many people who are born with TTP experience frequent flare-ups that need to be treated right away. TAK-755 is a medicine that replaces ADAMTS13 and may prevent or control TTP flare-ups, called acute TTP events. The main aim of the study is to check for side effects of long-term treatment with TAK-755. Treatment will be given in 2 ways: 1. TAK-755 treatment given either every week or every other week to prevent acute TTP events from happening (the "prophylactic" cohort). 2. TAK-755 treatment given to control an acute TTP event when it happens (the "on-demand" cohort). Participants in the prophylactic cohort will receive treatment in the clinic or at home for up to approximately 3 years. They will visit the clinic at least every 12 weeks. Participants in the on-demand cohort will receive daily treatment for the acute TTP event until the flare-up has gotten better. They will have a follow-up visit at the clinic 4 weeks later.

Conditions

  • Thrombotic Thrombocytopenic Purpura (TTP)

Interventions

  • TAK-755Biological

    TAK-755 IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Related Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Throughout the study period of approximately 6 years

Locations

27 sites in 11 countries. Site status is shown where the registry gives one.

  • Childrens Healthcare of Atlanta

    Atlanta, Georgia

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Mid Ohio Heart Clinic Inc

    Dublin, Ohio

  • University of Oklahoma

    Oklahoma City, Oklahoma

  • AKH - Medizinische Universität Wien

    Vienna, Austria

  • Beijing Children's Hospital

    Beijing, Beijing Municipality, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Tongji Hospital Affiliated to Tongji Medicine University

    Wuhan, Hubei, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsushe, China

  • Institute of Hematology and Hospital of Blood Disease

    Tianjin, Tianjin Municipality, China

  • Hôpital Saint-Antoine

    Paris, France

  • Hôpital Robert Debré- Paris

    Paris, France

  • Hôpital Necker - Enfants Malades

    Paris, Paris, France

  • CHU Saint Etienne - Hôpital Nord

    Saint-Priest-en-Jarez Cedex, Pays de la Loire Region, France

  • Universitaetsklinikum Hamburg-Eppendorf

    Hamburg, Germany

  • Universitaetsklinikum Jena, Klinik fuerKinder-und Jugendmedizin

    Jena, Germany

  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)

    Bergamo, Hubei, Italy

  • Kyushu University Hospital

    Fukuoka, Fukuoka, Japan

  • Hyogo College of Medicine Hospital

    Nishinomiya, Hyōgo, Japan

  • Medical Hospital,Tokyo Medical and Dental University

    Bunkyo City, Tokyo, Japan

  • Samodzielny Publiczny Dzieciecy Szpital Kliniczny

    Warsaw, Poland

  • Instytut Hematologii i Transfuzjologii

    Warsaw, Poland

  • Complejo Hospitalario Universitario A Coruña

    A Coruña, La Coruña, Spain

  • Hospital de Cruces

    Barakaldo, Vizcaya, Spain

  • Inselspital -Universitaetsspital Bern

    Bern, Switzerland

  • University College London Hospitals

    London, Greater London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.